Login / Signup

Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.

Tina RoyJoseph B AnKimberly DoucetteAimee M ChappellDavid H Vesole
Published in: Leukemia & lymphoma (2022)
Keyphrases
  • poor prognosis
  • single cell
  • acute myeloid leukemia
  • cell therapy
  • bone marrow
  • long non coding rna
  • mesenchymal stem cells